Publications

Export 11 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
., E. M. G., S. B.A., A. A.A., and A. E. - L. H.A., Treatment of Ulcerative Colitis Induced by Iodoacetamide in Rats, , 2014.
R
Mai A. Elhemely, Hany A. Omar, A. A. - S. A., H. A. A. El-latif, A. M. Abo-youssef, and G. E. A. Sherbiny, Rosuvastatin and ellagic acid protect against soproterenol-induced myocardial infarction in hyperlipidemic rats, , 2014.
El-Naggar1, A. R., D. Zaafar2, M. Elyamany3, S. Hassanin4, A. Bassyouni5, and undefined, "The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients", Journal of Cardiovascular Pharmacology and Therapeutics, vol. 24, issue 3, pp. :254-261, 2019.
P
I
El-Malky, W., A. M. Mahfouz, A. O. Osman, and H. A. A. El-latif, "Investigation of the impacts of zamzam water on streptozotocin-induced diabetic nephropathy in rats. In-vivo and in-vitro study", Biomedicine and Pharmacotherapy, vol. 138, pp. 1-8, 2021. 1-s2.0-s0753332221002596-main_1.pdf
Abdeltawab1, M. S. A., S. A. Rifaie1, E. Y. Shoeib1, A. H. A. El-Latif2, M. Badawi3, W. H. Salama4, and 5 A. A. Abd El-Aal1, "Insights into the impact of Ivermectin on some protein aspects linked to Culex pipiens digestion and immunity", Parasitology Research, vol. 119(1), issue 1, pp. 55-60, 2019.
Zayed, E. A., A. A. Ainshoka, K. E. A. Shazly, and undefined, "Improvement of insulin resistance via increase of GLUT4 and PPARγ in metabolic syndrome‐induced rats treated with omega‐3 fatty acid or L‐carnitine", Biochem Mol Toxicol. 2018, pp. 1-6, 2018.
H
Mohammed, T. Y., H. A. El-Tawab, undefined, and M. O., "hekma", Der Pharmacia Lettre, vol. 10 (1), pp. 11-23, 2018.
E
Mahmoud, H. M., H. F. Zaki, G. E. A. Sherbiny, and H. A. A. El-latif, Effects of Simvastatin and Vitamin E on Diet-Induced Hypercholesterolemia in Rats, , 2014.
A
Mahfoz, A. M., H. A. A. El-latif, L. A. Ahmed, N. M. Hassanein, and A. A. Shoka, "Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.", Naunyn-Schmiedeberg's archives of pharmacology, vol. 389, issue 12, pp. 1315-1324, 2016 Dec. Abstracta_a_citations.txt

Since chronic kidney disease due to diabetic nephropathy (DN) is becoming an ever larger health burden worldwide, more effective therapies are desperately needed. In the present study, the anti-diabetic and renoprotective effects of aliskiren have been evaluated in streptozotocin (STZ)-induced DN in rats. DN was induced by a single intraperitoneal injection of STZ (65 mg/kg). Three weeks after STZ, rats were divided into four groups; normal, diabetic, diabetic treated with gliclazide (10 mg/kg/day) for 1 month, and diabetic treated with aliskiren (50 mg/kg/day) for 1 month. At the end of the experiment, mean arterial blood pressure and heart rate were recorded. Rats were then euthanized and serum was separated for determination of glucose, insulin, kidney function tests, superoxide dismutase activity (SOD), adiponectin, and tumor necrosis factor-alpha (TNF-α). One kidney was used for estimation of malondialdehyde (MDA), reduced glutathione (GSH), and nitric oxide (NO) contents. Other kidney was used for histopathological study and immunohistochemical measurement of caspase-3 and transforming growth factor beta (TGF-β). In addition, islets of Langerhans were isolated from normal rats by collagenase digestion technique for in vitro study. Aliskiren normalized STZ-induced hyperglycemia, increased insulin level both in vivo and in vitro, normalized kidney function tests and blood pressure, and alleviated STZ-induced kidney histopathological changes. This could be related to the ability of aliskiren toward preserving hemodynamic changes and alleviating oxidative stress and inflammatory and apoptotic markers induced by STZ in rats. However, aliskiren was more effective than gliclazide in relieving STZ-induced DN. These findings support the beneficial effect of aliskiren treatment in DN which could be attributed to its anti-diabetic, renoprotective, antioxidant, anti-inflammatory, and anti-apoptotic effects. Moreover, clinical studies are required to establish the effectiveness of aliskiren treatment in patients suffering from hypertension and diabetes.